Page 16 - ASPIRE AUGUST 2022 Vol 7 Issue 3

NEW ZEALAND
Former ASPIRE Young
Investigator Award
winner is our new
correspondent in NZ
Introducing Dr Emily Liu Country Representative
Dr Emily Liu is the new ASPIRE country representative for New Zealand taking over this important role from Professor Neil Johnson.
Emily is well known among members as a winner of the ASPIRE Young Investigator Award at our Congress in Taipei in 2018. Her presentation was on a randomised controlled study of intra-uterine insemination versus expectant management in couples with unexplained infertility, which was subsequently published in The Lancet.
Based in Auckland, Emily is a fertility specialist and gynaecologist with Fertility Plus and Repromed, and she is a member of the Ethics Committee on Assisted Reproductive Technology (ECART) with the New Zealand Ministry of Health.
14
A graduate of the University of Otago, Emily gained her Master of Reproductive Medicine at the University of New South Wales, Australia in 2015. She is a Fellow of the Royal Australian and New Zealand College of Obstetrics and Gynaecology and holds Sub-Specialty Certification in Reproductive Endocrinology and Infertility.
“I am very excited to become the ASPIRE country representative for New Zealand and look forward to contributing to the newsletter and in other forums across the region,” Emily said.
“ASPIRE is a relatively young organisation compared with bodies such as the European Society of Human Reproduction and Embryology, the American Society for Reproductive Medicine, the British Fertility Society and the Fertility Society of Australia and New Zealand.
Emily Liu
“However, ASPIRE has achieved an enviable record in reproductive science creating many opportunities for researchers in the Asia Pacific.
“With such a large population base, research data across the Asia Pacific region in huge creating great potential to contribute to global knowledge in assisted reproduction.
“Meanwhile, we are currently challenged by a second wave of COVID in New Zealand creating staff shortages, but IVF units are attempting to do business as normal.”